Boston CE marks Express2 coronary stent:
This article was originally published in Clinica
Boston Scientific has CE-marked for sale in Europe its Express2 coronary stent system. The product features the company's Bioslide hydrophilic coating, designed to reduce friction, its proprietary Crimp 360 technology, which secures the stent to the balloon, and a laser-bonded, flexible tip with a long, low profile that allows for easier tracking. The stent, which is also expected to provide a platform for Boston's Taxus drug-eluting stent programme, is scheduled for launch in Europe next week. A US launch is expected in September.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.